Omnes Capital's investments: NH TherAguix

Sector 
Pharma
Entry Date 
04/2019
Business 
Venture Capital

NH TherAguix

Nanomedicine for cancer radiotherapy
Founded in December 2015, and backed by Pulsalys, the technology transfer acceleration company from Lyon Saint-Etienne, NH TherAguix originates a nanomedicine innovation, the AGuIX drug candidate. This product, thanks to its nanometric structure, allows an IV administration and combines three essential attributes to fight tumours: targeting, imaging and treatment. The AGuIX technology is therefore part of the theranostics concept, which relates to a combination of therapy (radiosensitizing effect) and diagnostics (MRI imaging), and more widely in the personalized medicine of tomorrow.
Latest news